We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Adicet Bio, Inc. (ACET - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of the Medical sector. This group includes 1064 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACET's full-year earnings has moved 28.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ACET has gained about 8.5% so far this year. Meanwhile, the Medical sector has returned an average of 7.3% on a year-to-date basis. This means that Adicet Bio, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Adma Biologics (ADMA - Free Report) . The stock is up 33.2% year-to-date.
For Adma Biologics, the consensus EPS estimate for the current year has increased 81.6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual companies and currently sits at #79 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so ACET is performing better in this area. Adma Biologics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and Adma Biologics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Adicet Bio, Inc. (ACET - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of the Medical sector. This group includes 1064 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACET's full-year earnings has moved 28.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ACET has gained about 8.5% so far this year. Meanwhile, the Medical sector has returned an average of 7.3% on a year-to-date basis. This means that Adicet Bio, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Adma Biologics (ADMA - Free Report) . The stock is up 33.2% year-to-date.
For Adma Biologics, the consensus EPS estimate for the current year has increased 81.6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual companies and currently sits at #79 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so ACET is performing better in this area. Adma Biologics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adicet Bio, Inc. and Adma Biologics as they could maintain their solid performance.